FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103563357> ?p ?o ?g. }

• W2103563357 endingPage "1260" @default.
• W2103563357 startingPage "1252" @default.
• W2103563357 abstract "Purpose This phase III study compared the efficacy and safety of bevacizumab (BV) when combined with several standard chemotherapy regimens versus those regimens alone for first-line treatment of patients with human epidermal growth factor receptor 2–negative metastatic breast cancer. Patients and Methods Patients were randomly assigned in 2:1 ratio to chemotherapy plus BV or chemotherapy plus placebo. Before random assignment, investigators chose capecitabine (Cape; 2,000 mg/m 2 for 14 days), taxane (Tax) -based (nab-paclitaxel 260 mg/m 2 , docetaxel 75 or 100 mg/m 2 ), or anthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, or fluorouracil/doxorubicin/cyclophosphamide]) chemotherapy administered every 3 weeks. BV or placebo was administered at 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), 1-year survival rate, objective response rate, duration of objective response, and safety. Two independently powered cohorts defined by the choice of chemotherapy (Cape patients or pooled Tax/Anthra patients) were analyzed in parallel. Results RIBBON-1 (Regimens in Bevacizumab for Breast Oncology) enrolled 1,237 patients (Cape cohort, n = 615; Tax/Anthra cohort, n = 622). Median PFS was longer for each BV combination (Cape cohort: increased from 5.7 months to 8.6 months; hazard ratio [HR], 0.69; 95% CI, 0.56 to 0.84; log-rank P < .001; and Tax/Anthra cohort: increased from 8.0 months to 9.2 months; HR, 0.64; 95% CI, 0.52 to 0.80; log-rank P < .001). No statistically significant differences in OS between the placebo- and BV-containing arms were observed. Safety was consistent with results of prior BV trials. Conclusion The combination of BV with Cape, Tax, or Anthra improves clinical benefit in terms of increased PFS in first-line treatment of metastatic breast cancer, with a safety profile comparable to prior phase III studies." @default.
• W2103563357 created "2016-06-24" @default.
• W2103563357 creator A5015144369 @default.
• W2103563357 creator A5019547742 @default.
• W2103563357 creator A5022422153 @default.
• W2103563357 creator A5031499770 @default.
• W2103563357 creator A5041912334 @default.
• W2103563357 creator A5042452774 @default.
• W2103563357 creator A5044108002 @default.
• W2103563357 creator A5054203615 @default.
• W2103563357 creator A5056565799 @default.
• W2103563357 creator A5065306642 @default.
• W2103563357 creator A5075481530 @default.
• W2103563357 creator A5080006341 @default.
• W2103563357 date "2011-04-01" @default.
• W2103563357 modified "2023-10-11" @default.
• W2103563357 title "RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer" @default.
• W2103563357 cites W1924346446 @default.
• W2103563357 cites W1991070664 @default.
• W2103563357 cites W2025689023 @default.
• W2103563357 cites W2095540788 @default.
• W2103563357 cites W2100669312 @default.
• W2103563357 cites W2107540411 @default.
• W2103563357 cites W2114159573 @default.
• W2103563357 cites W2126275851 @default.
• W2103563357 cites W2137131274 @default.
• W2103563357 cites W2139248078 @default.
• W2103563357 cites W2145835533 @default.
• W2103563357 cites W2157769714 @default.
• W2103563357 cites W2158679766 @default.
• W2103563357 cites W2159329940 @default.
• W2103563357 cites W2163003060 @default.
• W2103563357 cites W2165819904 @default.
• W2103563357 cites W2166602936 @default.
• W2103563357 cites W2176579253 @default.
• W2103563357 cites W2247075085 @default.
• W2103563357 doi "https://doi.org/10.1200/jco.2010.28.0982" @default.
• W2103563357 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21383283" @default.
• W2103563357 hasPublicationYear "2011" @default.
• W2103563357 type Work @default.
• W2103563357 sameAs 2103563357 @default.
• W2103563357 citedByCount "860" @default.
• W2103563357 countsByYear W21035633572012 @default.
• W2103563357 countsByYear W21035633572013 @default.
• W2103563357 countsByYear W21035633572014 @default.
• W2103563357 countsByYear W21035633572015 @default.
• W2103563357 countsByYear W21035633572016 @default.
• W2103563357 countsByYear W21035633572017 @default.
• W2103563357 countsByYear W21035633572018 @default.
• W2103563357 countsByYear W21035633572019 @default.
• W2103563357 countsByYear W21035633572020 @default.
• W2103563357 countsByYear W21035633572021 @default.
• W2103563357 countsByYear W21035633572022 @default.
• W2103563357 countsByYear W21035633572023 @default.
• W2103563357 crossrefType "journal-article" @default.
• W2103563357 hasAuthorship W2103563357A5015144369 @default.
• W2103563357 hasAuthorship W2103563357A5019547742 @default.
• W2103563357 hasAuthorship W2103563357A5022422153 @default.
• W2103563357 hasAuthorship W2103563357A5031499770 @default.
• W2103563357 hasAuthorship W2103563357A5041912334 @default.
• W2103563357 hasAuthorship W2103563357A5042452774 @default.
• W2103563357 hasAuthorship W2103563357A5044108002 @default.
• W2103563357 hasAuthorship W2103563357A5054203615 @default.
• W2103563357 hasAuthorship W2103563357A5056565799 @default.
• W2103563357 hasAuthorship W2103563357A5065306642 @default.
• W2103563357 hasAuthorship W2103563357A5075481530 @default.
• W2103563357 hasAuthorship W2103563357A5080006341 @default.
• W2103563357 hasBestOaLocation W21035633571 @default.
• W2103563357 hasConcept C121608353 @default.
• W2103563357 hasConcept C126322002 @default.
• W2103563357 hasConcept C141071460 @default.
• W2103563357 hasConcept C143998085 @default.
• W2103563357 hasConcept C168563851 @default.
• W2103563357 hasConcept C203092338 @default.
• W2103563357 hasConcept C207103383 @default.
• W2103563357 hasConcept C2775930923 @default.
• W2103563357 hasConcept C2776694085 @default.
• W2103563357 hasConcept C2776755627 @default.
• W2103563357 hasConcept C2776802502 @default.
• W2103563357 hasConcept C2777802072 @default.
• W2103563357 hasConcept C2777909004 @default.
• W2103563357 hasConcept C2780835546 @default.
• W2103563357 hasConcept C2781190966 @default.
• W2103563357 hasConcept C44249647 @default.
• W2103563357 hasConcept C526805850 @default.
• W2103563357 hasConcept C530470458 @default.
• W2103563357 hasConcept C71924100 @default.
• W2103563357 hasConcept C72563966 @default.
• W2103563357 hasConcept C90924648 @default.
• W2103563357 hasConceptScore W2103563357C121608353 @default.
• W2103563357 hasConceptScore W2103563357C126322002 @default.
• W2103563357 hasConceptScore W2103563357C141071460 @default.
• W2103563357 hasConceptScore W2103563357C143998085 @default.
• W2103563357 hasConceptScore W2103563357C168563851 @default.
• W2103563357 hasConceptScore W2103563357C203092338 @default.
• W2103563357 hasConceptScore W2103563357C207103383 @default.
• W2103563357 hasConceptScore W2103563357C2775930923 @default.
• W2103563357 hasConceptScore W2103563357C2776694085 @default.

• next